New concepts for anticoagulant therapy in persons with hemophilia

Slides:

Advertisements

Similar presentations

A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in.

Advertisements

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2): July 10, 2012 Copyright.

Changes in Body Weight After Total Hip Arthroplasty: Short-term and Long-term Effects by Nienke Paans, Martin Stevens, Robert Wagenmakers, Jan van Beveren,

Cerebral Small Vessel Disease In Patients With Sickle Cell Disease: Initial Findings With Ultra-High Field 7T MRI by Veronica van der Land, Jaco J.M. Zwanenburg,

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

Frontiers of anticoagulation therapy for atrial fibrillation

Atrial Fibrillation and Mortality in Heart FailureClinical Perspective

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis by Samantha C. Gouw, H. Marijke.

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Bleeding in carriers of hemophilia

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim.

Nonmyeloablative conditioning for relapsed follicular lymphoma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Catheter-related deep venous thrombosis in children with hemophilia

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Genetic sequence analysis of inherited bleeding diseases

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Protease inhibitors potentiate chemotherapy-induced neutropenia

How we choose factor VIII to treat hemophilia

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.

by Sabah Sallah, and Jim Y. Wan

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.

Shadi Al Halabi et al. JACEP 2015;1:

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Evidence Supporting Idarucizumab for the Reversal of Dabigatran

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

James L. Cox, MD, Niv Ad, MD, Terry Palazzo, RN, MS

Catheter Ablation for Atrial Fibrillation

How I treat cancer-associated venous thromboembolism

by Nicola Adderley, Ronan Ryan, and Tom Marshall

The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.

Moussa Mansour et al. JACEP 2016;j.jacep

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Termination of anticoagulation therapy at 45 days after concomitant atrial fibrillation catheter ablation and left atrial appendage occlusion resulting.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.

Jeffrey Y. Lin, MD, Petar Igic, MD, FHRS, Kurt S

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Volume 2(Supplement 1):39-41

Forest plot illustrating the risk ratio of any bleeding and GRADE assessment. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI,

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Forest plot illustrating the risk ratio of major bleeding

Forest plot of all-cause mortality (ACM) in CRT patient with AF comparing atrioventricular junction ablation (AVJA) versus no AVJA. AF, atrial fibrillation;

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

Temporal trends of AF hospitalisation per 100 patients with AF according to main hospitalisation causes between 2006 and *P value for increase trends

by John Robson, Kate Homer, Zaheer Ahmed, and Sotiris Antoniou

Forest plot illustrating the risk ratio of myocardial infarction

Forest plot illustrating risk ratio of stent thrombosis

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients by Elena.

by Renato D. Lopes, Patrícia O. Guimarães, Bradley J. Kolls, Daniel M

Cold agglutinin disease

Presentation transcript:

New concepts for anticoagulant therapy in persons with hemophilia by Roger E. G. Schutgens, Jeroen F. van der Heijden, Eveline P. Mauser-Bunschoten, and Pier M. Mannucci Blood Volume 128(20):2471-2474 November 17, 2016 ©2016 by American Society of Hematology

Recommendation for anticoagulant therapy in hemophilia patients with atrial fibrillation. Recommendation for anticoagulant therapy in hemophilia patients with atrial fibrillation. Compared with our previous flowchart,2 notice the following adaptations: baseline FVIII/FIX changed from 30% to 20%; CHADS2 changed to CHA2DS2VASC; DOAC added; in patients with factor levels 1% to 20%, the threshold for the CHA2DS2VASC is raised to 4 and the option of catheter ablation is added. Roger E. G. Schutgens et al. Blood 2016;128:2471-2474 ©2016 by American Society of Hematology